Sangamo Therapeutics, Inc. filed a current report on October 27, 2026, disclosing the submission of amended monthly operating reports for July and August 2026 and a new monthly operating report for September 2026 with the United States Bankruptcy Court for the District of Delaware.

Key Highlights

  • Chapter 11 filing: Sangamo Therapeutics commenced its Chapter 11 case on June 23, 2026, styled as In re Sangamo Therapeutics, Inc., case number 26-10989, in the District of Delaware.
  • Three operating reports submitted: On October 23, 2026, the company filed amended reports for July 1 - July 31, 2026 and August 1 - August 31, 2026, plus a new report covering September 1 - September 30, 2026.
  • Delisting completed: Nasdaq filed to delist the company's common stock on October 7, 2026, and the delisting became effective October 17, 2026.
  • OTC trading only: The company's common stock (OTC Expert Market: SGMOQ) currently trades on an unsolicited quotes only basis following suspension from Nasdaq on May 5, 2026.
  • Reports not audited: According to the filing, the monthly operating reports were not prepared under U.S. generally accepted accounting principles and are not audited or reviewed by independent accountants.
  • Trading caution issued: The company stated that "trading in the Company's common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks."

Sangamo's Bankruptcy Operating Reports and Delisting Status

Sangamo Therapeutics, a gene regulation and cell therapy company headquartered at 501 Canal Blvd., Richmond, California, voluntarily entered Chapter 11 bankruptcy protection on June 23, 2026. The current report, signed by Chief Legal Officer and Corporate Secretary Scott B. Willoughby, discloses that on October 23, 2026, the company submitted three monthly operating reports to the Bankruptcy Court: amended versions covering July and August 2026, and a new report covering September 2026. The amended July report had originally been filed with the SEC on September 8, 2026, and the amended August report had originally been filed on October 15, 2026.

The filing notes that the monthly operating reports are attached as Exhibits 99.1, 99.2, and 99.3, and that additional information about the Chapter 11 case is available at the case administrator's website. According to the filing, the reports "are limited in scope, cover a limited time period and have been prepared solely for the purpose of complying with the reporting requirements of the Bankruptcy Court." The company disclosed that the reports are subject to future adjustment and reconciliation, and that results in them "should not be viewed as indicative of future results."

On the securities side, Nasdaq suspended trading in Sangamo's common stock on May 5, 2026. Nasdaq subsequently filed a Form 25 with the SEC on October 7, 2026, and the delisting became effective October 17, 2026. The stock now trades on the OTC Expert Market under the symbol SGMOQ on an unsolicited quotes only basis. The company's filing cautions that "trading prices for the Company's common stock may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company's Chapter 11 Case."

What Was Disclosed

Sangamo Therapeutics disclosed its submission of three monthly operating reports to the Delaware bankruptcy court, covering July through September 2026, along with details of its completed Nasdaq delisting effective October 17, 2026, and the status of its ongoing Chapter 11 case numbered 26-10989.